| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2025-02-26 | 2028-08 | 2028-02 |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors | RECRUITING | PHASE1 | 2025-01-07 | 2026-12 | 2026-12 |
| NCT05787496 | A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms | TERMINATED | PHASE1 | 2023-02-28 | 2025-01-31 | 2025-01-31 |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-10-06 | 2025-11 | 2025-07 |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | WITHDRAWN | PHASE1, PHASE2 | 2021-12-06 | 2022-10-30 | 2022-06-30 |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2021-06-30 | 2024-01-30 | 2024-01-30 |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2020-06-10 | 2023-07-06 | 2023-07-06 |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2018-10-01 | 2023-04-11 | 2023-04-11 |